Skp to main content
Home

Main navigation

  • Advantage Hers
  • Our Company
    • About Us
    • Management
    • Sustainability
    • Health of the planet
    • Partnering
    • Suppliers
      • Requisition to Pay Process
      • Become our supplier
    • Disclosure Of Payments
      • Disclosure of payments to Healthcare Professionals
        • Denmark
        • Belgium
        • Finland
        • Sweden
        • Hungary
        • Italy
        • Netherlands
        • Ukraine
        • Ireland
        • Norway
        • Romania
    • Ethical Business Practices
    • USA
    • Other countries
  • Disease Areas
    • Disease areas
  • Our Science
    • Overview
    • Drug discovery
    • Capabilities
    • Clinical studies
    • Innovation is
    • Pipeline
  • Clinical Studies
    • Overview
    • Current studies
    • Clinical studies index
      • Alprazolam
      • Alprostadil (Prostavasin®)
      • Baclofen (Kemstro®)
      • Bepranemab (UCB0107)
      • Bimekizumab (Bimzelx®)
      • Brivaracetam (Briviact®)
      • CDP323
      • CDP791
      • Carbidopa,Levodopa (Parcopa®)
      • Certolizumab Pegol (Cimzia®)
      • Dapirolizumab pegol
      • Doxecitine and doxribtimine (KYGEVVI™)
      • Doxecitine and doxribtimine (MT1621)
      • Epratuzumab
      • Fenfluramine (Fintepla)
      • Ferrous(II) glycine sulphate complex (Ferro Sanol®)
      • Ginisortamab (UCB6114)
      • Glovadalen (UCB0022)
      • Hydrocodone Bitartrate controlled release (HC-CR)
      • Hydrocodone bitartrate extended release (HC-ER)
      • Intraject® Sumatriptan
      • Lacosamide (Vimpat®)
      • Levetiracetam (Keppra®)
      • Levocetirizine (Xyzal®)
      • MT1621
      • Olokizumab
      • Padsevonil (UCB0942)
      • Piracetam (Nootropil®)
      • Radiprodil
      • Risperidone-SABER®
      • Romosozumab (EVENITY®)
      • Rotigotine (Neupro®)
      • Rotigotine (Neupro®)
      • Rozanolixizumab (Rystiggo®)
      • Seletalisib (UCB5857)
      • Seletracetam
      • Staccato Alprazolam
      • UCB0022
      • UCB0059
      • UCB1381
      • UCB6114
      • UCB7853
      • UCB9741
      • Zampilimab (UCB7858)
      • Zilucoplan (Zilbrysq®)
    • Data Transparency Policy
  • Our Products
    • Products
    • Bimzelx®
    • Briviact®
    • Cimzia® - Ankylosing spondylitis (AS)
    • Cimzia® - Axial spondyloarthritis (axSpA)
    • Cimzia® - Crohn's disease
    • Cimzia® - Plaque psoriasis (PsO)
    • Cimzia® - Psoriatic arthritis (PsA)
    • Cimzia® - Rheumatoid arthritis (RA)
    • Evenity®
    • Fintepla®
    • Keppra®
    • Nayzilam
    • Neupro® - Parkinson's disease
    • Neupro® - Restless Legs Syndrome
    • Vimpat®
  • Newsroom
    • Overview
    • Press releases
    • Our stories
    • Resources
    • Contact
  • Healthcare Professionals
    • HCP Overview
    • Women of childbearing age
    • Immune to the impossible
  • Patients
    • Overview
    • Life stories
    • Women of Childbearing Age
  • Investors
    • Overview
    • UCB equity story
    • UCB Governance
    • UCB shareholders
      • Shareholders meeting 2021
    • ESG overview
    • Download center
    • IR team
  • Careers
    • Applying to UCB
Listen

UCB Japan Co. Ltd

Shinjuku Grand Tower
8-17-1 Nishi-Shinjuku
Shinjuku-ku
J - Tokyo 160-0023
Tel: +81 3 6864 7500
Fax: +81 3 6864 7501
E-mail: info_ucbj@ucb.com

Website: UCB Japan Co. Ltd

https://ucbcares.jp

Choose a Country

  • Global Site – English
  • Australia – English
  • België – Engels
  • Belgique – Anglais
  • Brasil – Português
  • България – Български
  • Canada – English
  • Canada – Français
  • 中国 – 中文
  • Česká Republika – Angličtina
  • Danmark – Engelsk
  • Deutschland – Deutsch
  • France – Français
  • España – Español
  • Ελλάδα – Ελληνικά
  • India – English
  • Ireland – English
  • Italia – Inglese
  • 日本 – 日本語
  • 한국 – 한국어
  • Luxembourg – Anglais
  • Luxemburg – Engels
  • Magyarország – Angol
  • México & Latinoamérica – Español
  • Nederland – Engels
  • New Zealand – English
  • Norge – Engelsk
  • Österreich – Deutsch
  • Polska – Polski
  • Portugal – español y portugués
  • România – Engleză
  • Россия – Русский
  • Slovensko – Anglický
  • Suomi – Englanti
  • Sverige – Engelska
  • Schweiz – Deutsch
  • Suisse – Français
  • Türkiye – Türkçe
  • Україна – Англійська
  • United Kingdom – English
  • U.S.A. – English
UCB Logo

© 2007 - 2025 UCB S.A., Belgium. All rights reserved. Last updated on: August, 18, 2025

Social media links

  • linkedin
  • instagram
  • facebook
  • twitter
  • youtube

Footer menu

  • Contact us
  • UCBCares®
  • UCB Worldwide
  • Legal Notice
  • Privacy Notice
  • Cookie policies
  • Cookie preferences
  • Payment disclosure
  • Sitemap
UCB Logo

© 2007 - 2025 UCB S.A., Belgium. All rights reserved. Last updated on: January, 05, 2026